The DDI2 Antibody (PACO36598) is a highly specific and sensitive tool for studying the function of CD300A, a key player in immune regulation. This polyclonal antibody, developed using advanced techniques, is optimized for detecting CD300A protein in human samples through Western blot analysis. With its high reactivity and reliability, researchers can confidently use this antibody to investigate the role of CD300A in various cell types, making it a valuable tool for studies in immunology and cancer research.
CD300A, also known as an immune inhibitory receptor, plays a crucial role in maintaining immune balance by suppressing immune responses and inflammatory reactions. Research on CD300A has shown its potential as a therapeutic target for diseases such as cancer, autoimmune disorders, and chronic inflammation. By understanding the functions of CD300A, researchers can develop novel approaches for manipulating immune responses in these disease contexts, leading to potential advancements in treatment strategies.
Western blot. All lanes: DDI2 antibody at 4µg/ml. Lane 1: A431 whole cell lysate. Lane 2: HL60 whole cell lysate. Lane 3: K562 whole cell lysate. Lane 4: Caco-2 whole cell lysate. Secondary. Goat polyclonal to rabbit IgG at 1/10000 dilution. Predicted band size: 45, 24, 47 kDa. Observed band size: 47 kDa.
Immunohistochemistry of paraffin-embedded human endometrial cancer using PACO36598 at dilution of 1:100.
Background:
Aspartic protease that mediates the cleavage of NFE2L1/NRF1 at 'Leu-104', thereby promoting release of NFE2L1/NRF1 from the endoplasmic reticulum membrane. Ubiquitination of NFE2L1/NRF1 is a prerequisite for cleavage, suggesting that DDI2 specifically recognizes and binds ubiquitinated NFE2L1/NRF1.
